BCG in Bladder Cancer Immunotherapy
BCG is a live attenuated strain of <i>Mycobacterium bovis</i> that is primarily used as a vaccine against tuberculosis. In the past four decades, BCG has also been used for the treatment of non-muscle invasive bladder cancer (NMIBC). In patients with NMIBC, BCG reduces the risk of tumor...
Main Authors: | Song Jiang, Gil Redelman-Sidi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/13/3073 |
Similar Items
-
Miliary Tuberculosis Due to BCG Immunotherapy
by: Bilgehan AYGEN, et al.
Published: (1996-03-01) -
BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
by: Sarah Lidagoster, et al.
Published: (2024-02-01) -
Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
by: Hakeem Sam, et al.
Published: (2020-12-01) -
Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’
by: Ahmed Ghonaimy, et al.
Published: (2022-02-01) -
Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
by: Ana T. Vilares, MD, et al.
Published: (2022-07-01)